Provided by Tiger Fintech (Singapore) Pte. Ltd.

Editas Medicine

3.23
-0.0350-1.07%
Volume:65.85K
Turnover:213.10K
Market Cap:269.97M
PE:-1.06
High:3.27
Open:3.27
Low:3.21
Close:3.26
Loading ...

Truist Financial Remains a Hold on Editas Medicine (EDIT)

TIPRANKS
·
2 hours ago

Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now?

Motley Fool
·
28 Jun

JonesTrading Sticks to Their Hold Rating for Editas Medicine (EDIT)

TIPRANKS
·
17 Jun

Editas Medicine Is Great. Here's Why You Shouldn't Buy It.

Motley Fool
·
17 Jun

Editas says levels of HBG1/2 promoter editing in hematopoietic stem cells

TIPRANKS
·
12 Jun

Editas Medicine Announces Breakthrough in In Vivo Gene Editing for Sickle Cell Disease and Beta Thalassemia at European Hematology Association 2025 Congress

Reuters
·
12 Jun

Editas Medicine Inc. EVP and Chief Scientific Officer Linda Burkly Reports Disposal of Common Shares

Reuters
·
05 Jun

Editas Medicine CEO Neil O'Neill Reports Disposal of Common Shares

Reuters
·
05 Jun

Editas Medicine Inc. Conducted Annual Stockholders Meeting

Reuters
·
03 Jun

Editas Medicine Inc. Unveils Innovative Gene Editing Strategies to Transform Therapeutics Globally

Reuters
·
29 May

Cautious Outlook on Editas Medicine: Hold Rating Amidst Preclinical Progress and Financial Considerations

TIPRANKS
·
17 May

Promising Preclinical Data and Market Opportunities Drive Buy Rating for Editas Medicine

TIPRANKS
·
16 May

BRIEF-Editas Medicine Reports New In Vivo Data Highlighting The Potential Of Editas’ Gene Upregulation Strategy In Hscs At The American Society Of Gene And Cell Therapy Annual Meeting

Reuters
·
14 May

Editas Medicine Announces Promising Preclinical Results for In Vivo Gene Editing Approach to Treat Sickle Cell Disease and Beta Thalassemia

Reuters
·
14 May

Editas Medicine Is Maintained at Outperform by Baird

Dow Jones
·
13 May

Editas Medicine Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
13 May

Editas Medicine Q1 EPS $(0.92) Misses $(0.59) Estimate, Sales $4.66M Beat $706.00K Estimate

Benzinga
·
13 May

Editas Medicine Inc. to Showcase Preclinical Gene Editing Advances at ASGCT Annual Meeting

Reuters
·
13 May

BRIEF-Editas Medicine Q1 Net Income USD -76.088 Million

Reuters
·
13 May

North American Morning Briefing: Stock Futures Surge on China Deal

Dow Jones
·
12 May